Reuters logo
Watson's buy of Swiss Actavis approved in EU
October 5, 2012 / 3:20 PM / 5 years ago

Watson's buy of Swiss Actavis approved in EU

BRUSSELS, Oct 5 (Reuters) - U.S. drugmaker Watson Pharmaceuticals Inc secured EU regulatory clearance on Friday to buy Swiss peer Actavis Group for at least 4.25 billion euros ($5.53 billion) to reinforce its international reach.

Watson, one of the world’s biggest suppliers of generic drugs, said in April that the deal would immediately boost earnings. It forecast synergies of more than $300 million within three years.

The European Commission said in a statement that the deal would not hurt competition.

“The investigation showed that despite significant changes in the competitive situation in some of the markets, a sufficient number of credible and strong competitors will continue to exercise a competitive constraint on the merged entity,” the EU watchdog said.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below